{"id":"metformin-plus-pioglitazone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin component)"},{"rate":null,"effect":"Heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets type 2 diabetes through complementary pathways: metformin acts primarily on the liver to decrease gluconeogenesis and improve peripheral glucose uptake, while pioglitazone increases insulin sensitivity in peripheral tissues by promoting glucose uptake and reducing hepatic glucose output. Together, they provide synergistic glycemic control by addressing both hepatic and peripheral insulin resistance.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while pioglitazone enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose and muscle tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:59.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05727761","phase":"PHASE2","title":"Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-01-01","conditions":"Oral Leukoplakia","enrollment":36},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06399835","phase":"PHASE4","title":"Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2024-02-01","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT06243536","phase":"PHASE4","title":"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2024-02-01","conditions":"Type 2 Diabetes, Overweight, Disordered Eating Behaviors","enrollment":60},{"nctId":"NCT05760677","phase":"PHASE1","title":"Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-10-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D","enrollment":142},{"nctId":"NCT05942963","phase":"PHASE4","title":"Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":"Non-Alcoholic Fatty Liver Disease, Type2diabetes","enrollment":240},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT05629806","phase":"PHASE3","title":"Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-04-10","conditions":"Type 2 Diabetes, Blood Glucose Fluctuation","enrollment":50},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT02303405","phase":"PHASE2","title":"Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2014-11","conditions":"Diabetes Mellitus Type 2 With Hyperglycemia","enrollment":22},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05519813","phase":"PHASE4","title":"Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.","status":"UNKNOWN","sponsor":"Bing He","startDate":"2022-01-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04976283","phase":"PHASE4","title":"Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver","status":"UNKNOWN","sponsor":"Getz Pharma","startDate":"2021-09-15","conditions":"Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD","enrollment":123},{"nctId":"NCT04867252","phase":"PHASE2","title":"Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2021-05-03","conditions":"PCOS","enrollment":88},{"nctId":"NCT03566225","phase":"EARLY_PHASE1","title":"Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-30","conditions":"Pioglitazone","enrollment":400},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":190},{"nctId":"NCT03950505","phase":"PHASE4","title":"To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-05-29","conditions":"Non-alcoholic Steatohepatitis, Type2 Diabetes","enrollment":60},{"nctId":"NCT03796975","phase":"PHASE4","title":"Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2018-06-28","conditions":"Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy","enrollment":120},{"nctId":"NCT03117517","phase":"EARLY_PHASE1","title":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2017-03-20","conditions":"Polycystic Ovarian Syndrome","enrollment":106},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT00694759","phase":"NA","title":"Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-10","conditions":"Polycystic Ovary Syndrome","enrollment":37},{"nctId":"NCT02763007","phase":"PHASE4","title":"An Extension Study of PEAK Trial","status":"TERMINATED","sponsor":"Kun-Ho Yoon","startDate":"2016-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT01882907","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2009-12","conditions":"Type 2 Diabetes","enrollment":287},{"nctId":"NCT00399204","phase":"PHASE4","title":"Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients","status":"WITHDRAWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2006-01","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT01972724","phase":"PHASE4","title":"Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-12-16","conditions":"Type II Diabetes Mellitus","enrollment":114},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT02733679","phase":"PHASE4","title":"Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone","status":"COMPLETED","sponsor":"NHS Tayside","startDate":"2016-09-29","conditions":"Ataxia-Telangiectasia","enrollment":27},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT02875821","phase":"PHASE4","title":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-04-26","conditions":"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)","enrollment":44},{"nctId":"NCT03196362","phase":"PHASE4","title":"Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT02298192","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-11-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00972283","phase":"PHASE3","title":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1006},{"nctId":"NCT00481663","phase":"PHASE2","title":"A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08-19","conditions":"Type II Diabetes Mellitus","enrollment":555},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00237237","phase":"PHASE3","title":"Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT03030300","phase":"PHASE4","title":"Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Qianfoshan Hospital","startDate":"2008-01","conditions":"Type2 Diabetes","enrollment":170},{"nctId":"NCT00133718","phase":"PHASE4","title":"A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control","status":"COMPLETED","sponsor":"Asker & Baerum Hospital","startDate":"2002-01","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT00849056","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01","conditions":"Diabetes Mellitus, Type 2","enrollment":310},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00396227","phase":"PHASE3","title":"Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":2665},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00909597","phase":"PHASE3","title":"A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-05","conditions":"Diabetes Mellitus Type 2","enrollment":756},{"nctId":"NCT00765817","phase":"PHASE3","title":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":261},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT00744367","phase":"PHASE3","title":"A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Diabetes Mellitus Type 2","enrollment":326},{"nctId":"NCT01612858","phase":"PHASE4","title":"Metabolic Abnormalities in HIV-infected Persons","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2011-06","conditions":"Lipodystrophy, HIV Infection","enrollment":20},{"nctId":"NCT00437970","phase":"PHASE4","title":"Medication in Early Diabetes (MED) Study","status":"WITHDRAWN","sponsor":"Menzies School of Health Research","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02683226","phase":"PHASE4","title":"Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2015-03","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":30},{"nctId":"NCT02142309","phase":"PHASE4","title":"Glycemic Durability After Metformin Failure","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":450},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT00219440","phase":"PHASE4","title":"A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2003-02","conditions":"Diabetes Mellitus","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":135,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin plus pioglitazone","genericName":"Metformin plus pioglitazone","companyName":"Nanjing First Hospital, Nanjing Medical University","companyId":"nanjing-first-hospital-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while pioglitazone enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose and muscle tissue. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}